By Fineline Cube 
The 2025 National Medical Insurance (MediCare) Negotiation kicked off at 8:30 AM, marking the start of a 4‑ to 5‑day process that will shape the country’s Basic Medical Insurance Drug Catalogue and the Commercial Insurance Innovative Drug Catalogue.
Negotiation Timeline & Focus
| Day | Session | Key Activity |
|---|---|---|
| 1 | Opening | Basic Medical Insurance Drug Catalogue negotiations |
| 2‑4 | Continuation | Price consultations for the Commercial Insurance Innovative Drug Catalogue |
| 5 | Closure | Final agreements and public release of catalogue updates |
2025 Basic Medical Insurance Drug Catalogue – Generic Drug Review
- Total generic names reviewed: 535
- Outside the catalogue: 311
- Already within the catalogue: 224
These figures reflect the preliminary assessment carried out by the Ministry of Health and the National Health Commission, setting the stage for potential inclusion or removal of drugs in the upcoming catalogue.
Commercial Insurance Innovative Drug Catalogue – Generic Drug Review
- Total generic names reviewed: 121
- Applying for both Basic & Commercial catalogues: 79
The overlapping applications indicate a strategic push to streamline drug coverage across both public and commercial insurance systems.
Implications for Market Players
- Pharmaceutical Companies – Must prepare for price negotiations and potential adjustments to reimbursement rates.
- Healthcare Providers – Will need to update formulary management systems to align with new catalogue listings.
- Patients – Anticipate changes in drug coverage and out‑of‑pocket costs once the catalogue is finalized.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech